Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of T2DM and has an important role in weight loss. Also, it may represent a new therapeutic option for the treatment of MASH in obese diabetic patients. The main outcomes were...
When results were stratified by diabetes duration, weight loss reduction was estimated for all intervals, with greatest weight reduction in participants having lived with diabetes for less than 1 year (Fig. 3C). A statistically significant interaction (P = 0.047) was found between diabetes...
After administration of general anesthesia (Ketamine 100 mg/kg body weight and Xylazine 10 mg/kg body weight) by intraperitoneal injections, rats were fixed in a standard stereotaxic frame (RWD Life Science in Shenzhen, China) and received a single injection of 6-OHDA (2 mg/ml ...
Blood pressure was measured using a standardized cuff adapted to the size of the participant’s arm after the participant had rested in a sitting position for at least 5 min. Height was recorded in centimetres and body weight in kilograms, to one decimal place, while the participant was...
A 16-week time point is the earliest time frame to assess the effect of GLP-1 RAs on body mass in those who respond to therapy. We hypothesize that the expected changes in body mass weight also reflects in taste perception and neural response. The injection should be given before bedtime,...